Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 401–500 of 856
Molecular mechanisms of Alzheimer’s disease: From therapeutic targets to promising drugs
Alan, E., Kerry, Z., & Sevin, G. (2023) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12861 · Cited by 17
“Aβ may impair mitochondrial function both by causing cellular changes (indirect) such as ROS production and disruption of calcium homeostasis and inducing the aggregation of proteins, as well as by its direct effects on mitochondria.(126) Aβ and hyperphosphorylated tau may disrupt mitochondrial Ca homeostasis by incre…”
BackgroundInfluentialImpaired Synaptic Plasticity Mechanisms in Alzheimer’s Disease
Ebrahimi, R., Golzari, Z., Heidari‐Foroozan, M., Khosravi, A., Sharghi, S. G., Saleh, M., Salarvandian, S., & Esmaeilpour, K. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01712-9 · Cited by 23
“Sev‑ eral studies indicate that mitochondrial dysfunction may occur before or in parallel with Aβ pathology, challeng ‑ ing the traditional amyloid cascade hypothesis (Mao et al. 2012; Swerdlow 2018 ).”
Li, H.-L., Zhang, S., Ren, Y., Zhou, J., Zhou, Y.-X., Huang, W., Piao, X., Yang, Z., Wang, S., & Ge, Y. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.966276 · Cited by 17
“Therefore, other mitochondrial parameters should also be considered and included in the scope of investigation, such as increased oxidative stress markers and Aβ production and decreased ATP level and oxygen consumption (20).”
BackgroundGenetic Networks of Alzheimer’s Disease, Aging, and Longevity in Humans
Balmorez, T., Sakazaki, A., & Murakami, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065178 · Cited by 17
Li, S., Wang, Y., Zhang, X., Xiong, X., Zhou, F., Li, X., Fan, J., Liang, X., Li, G., Peng, Y., et al. (2023) · Metabolomics · doi:10.1007/s11306-023-02023-9 · Cited by 18
“Mitochondrial changes include a decrease in the number of mitochondria, a shorter and wider shape, disappearance of the bilayer membrane structure, irregular dorsal cristae of the inner mitochondrial membrane, and oedema of the mitochondrial matrix (Swerdlow, 2018).”
BackgroundYan, R., Wang, W., Yang, W., Huang, M., & Xu, W. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230314 · Cited by 23
Laparra, I. C., Juárez‐Escoto, E., Vicario‐Abejón, C., Moratalla, R., & García‐Sanz, P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1087072 · Cited by 17
“Therefore, mitochondrial dysfunction is closely linked to AD pathogenesis (Swerdlow, 2018; Perez Ortiz and Swerdlow, 2019; Castora et al., 2022).”
BackgroundMitochondrial Interaction with Serotonin in Neurobiology and Its Implication in Alzheimer’s Disease
Tian, J., Du, E. Y., & Guo, L. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230070 · Cited by 20
Modulation of Mitochondrial Function as a Therapeutic Strategy for Neurodegenerative Diseases
Trushina, E. V., Nguyen, T. K. O., & Trushin, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.108 · Cited by 17
“The “mitochondrial cascade hypothesis” proposes that an individual’s genetic predisposition, environmental exposure, and lifestyle could affect mitochondrial function and mediate, drive, and/or contribute to a variety of AD pathologies (50).”
BackgroundMaruthiyodan, S., Mumbrekar, K. D., & Guruprasad, K. P. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101868 · Cited by 21
Kugler, B. A., Lysaker, C. R., Franczak, E., Hauger, B. M., Csikós, V., Stopperan, J. A., Allen, J., Stanford, J. A., Koch, L. G., Britton, S. L., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01248-3 · Cited by 19
The emerging role of oxygen redox in pathological progression of disorders
Li, S.-Y., Gong, X., Ndikuryayo, F., & Yang, W. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102660 · Cited by 18
Hawkins, K., & Duchen, M. R. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i5.236 · Cited by 18
Eckert, G. P., Eckert, S. H., Eckmann, J., Hagl, S., Muller, W. E., & Friedland, K. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113286 · Cited by 21
Toward refining Alzheimer's disease into overlapping subgroups
Hascup, E. R., & Hascup, K. N. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12070 · Cited by 18
Li, H., Uittenbogaard, M. N., Hao, L., & Chiaramello, A. (2021) · Metabolites · doi:10.3390/metabo11040233 · Cited by 20
Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion
Nishimura, A. L., & Arias, N. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.660693 · Cited by 19
Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
Ilina, A., Khavinson, V., Linkova, N. S., & Petukhov, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084259 · Cited by 18
“Proponents of the theory of the mitochondrial cascade [44] indicate the primacy of mitochondrial disorders in AD pathogenesis, emphasizing the influence of ROS on APP processing [45] and dysregulation of mitochondrial processes in cytoplasmic hybrid (cybrid) cell lines containing mtDNA of AD patients.”
BackgroundThe endocannabinoid system: a bridge between alzheimer’s disease and gut microbiota
Bisogno, T., Lauritano, A., & Piscitelli, F. (2021) · Life · doi:10.3390/life11090934 · Cited by 16
Gao, Z., Zhang, R., Jiang, L., Zhou, H., Wang, Q., Ma, Y., Zhang, D., Qin, Y., Tian, P., Zhang, N., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215301 · Cited by 18
SARM1 participates in axonal degeneration and mitochondrial dysfunction in prion disease
Lai, M., Li, J., Zhang, X., Wu, W., Li, Z., Sun, Z., Zhao, M., Yang, D., Wang, D., Li, W., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.337051 · Cited by 17
“As the main producer of energy in cells, mitochondria are involved in many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and prion disease (Pacelli et al., 2015; Swerdlow, 2018; Wu et al., 2019; Zhang et al., 2020; Wang et al., 2021).”
BackgroundJett, S., Dyke, J. P., Boneu, C., Zarate, C., Carlton, C., Schelbaum, E., Jang, G., Pahlajani, S. S., Williams, S., Brinton, R. D., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281302 · Cited by 18
Gul, S., Attaullah, S., Alsugoor, M. H., Bawazeer, S., Shah, S. A., Khan, S., Salahuddin, H. S., & Ullah, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16930 · Cited by 18
“Mechanism which leads to synaptic loss and memory impairment in Alzheimer disease are not well understood but it is reported that due to soluble oligomers of amyloid beta, synaptic toxicity develops which leads to the development of Alzheimer disease [10,20,21,22].”
BackgroundWang, Y., Zou, J., Wang, Y., Wang, J., Ji, X., Zhang, T., Chu, Y., Cui, R., Zhang, G., Shi, G., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109706 · Cited by 16
“119 Mitochondrial dysfunction and oxidative stress may further trigger Aβ 120 aggregation and a range of abnormal alterations (Swerdlow, 2018).”
BackgroundGhosh, P., Shokeen, K., Mondal, S., Kandasamy, T., Kumar, S., Ghosh, S. S., & Iyer, P. K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00473 · Cited by 17
Xie, Y., Ke, X., Ye, Z., Li, X., Chen, Z., Liu, J., Wu, Z., Liu, Q., & Du, X. (2024) · Food & Function · doi:10.1039/d4fo00520a · Cited by 18
Changes in the expression of oxidative phosphorylation complexes in the aging intestinal mucosa
Özsoy, M., Zimmermann, F., Feichtinger, R. G., Mayr, J. A., Kofler, B., Neureiter, D., Klieser, E., Schütz, S., Weghuber, D., & Schneider, A.-M. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110924 · Cited by 17
Dynamic Interplay between Copper Toxicity and Mitochondrial Dysfunction in Alzheimer’s Disease
Tassone, G., Kola, A., Valensin, D., & Pozzi, C. (2021) · Life · doi:10.3390/life11050386 · Cited by 22
Pharmacologic enrichment of exosome yields and mitochondrial cargo
Wang, X., Berkowicz, A., King, K., Menta, B. W., Gabrielli, A. P., Novikova, L., Troutwine, B., Pleen, J., Wilkins, H., & Swerdlow, R. H. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.04.001 · Cited by 22
Self-citationWeller, A. E., Ferraro, T. N., Doyle, G. A. R., Reiner, B. C., Crist, R. C., & Berrettini, W. H. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220391 · Cited by 17
Mitochondria Profoundly Influence Apolipoprotein E Biology
Gabrielli, A. P., Weidling, I. W., Ranjan, A., Wang, X., Novikova, L., Chowdhury, S. R., Menta, B. W., Berkowicz, A., Wilkins, H., Peterson, K. R., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221177 · Cited by 18
Self-citationReview of FUNDC1-mediated mitochondrial autophagy in Alzheimer’s disease
Shi, D., Guo, X., Ning, Z., Zhang, Y., Liu, F., Liu, M., & Wei, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1544241 · Cited by 18
“…and animal models of AD (e.g., APP/PS1 mice), neurons exhibit hallmark mitochondrial defects, including fragmented morphology, elevated mtDNA deletions, and impaired cytochrome c oxidase (COX) activity—a key indicator of oxidative phosphorylation failure (Swerdlow, 2018; Tran and Reddy, 2020).”
AI-assisted multi-OMICS analysis reveals new markers for the prediction of AD
Latifi‐Navid, H., Mokhtari, S., Taghizadeh, S., Moradi, F., Poostforoush-Fard, D., Alijanpour, S., & Aghanoori, M. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167925 · Cited by 19
Is Mitochondria DNA Variation a Biomarker for AD?
Gao, R., & Ma, S. L. (2022) · Genes · doi:10.3390/genes13101789 · Cited by 15
“Some studies have indicated that upstream pathologies, including Aβ, cause mitochondrial dysfunction, while others have suggested that mitochondrial dysfunction occurs independently of Aβ and directly disrupts brain functions or subsequently introduces other pathologies that lead to neurodegeneration [14].”
BackgroundAmerican Ginseng for the Treatment of Alzheimer’s Disease: A Review
Shan, M., Bai, Y., Fang, X., Lan, X., Zhang, Y., Cao, Y., Zhu, D., & Luo, H. (2023) · Molecules · doi:10.3390/molecules28155716 · Cited by 16
Zhu, Y., Huang, H., Chen, Z., Tao, Y. K., Liao, L., Gao, S.-H., Wang, Y., & Gao, C.-Y. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01098-7 · Cited by 20
“Indeed, previous studies have shown that altered mitochondrial energy metabolism drives changes in APP and Aβ homeostasis [59].”
Tian, J., Jia, K., Wang, T., Guo, L., Xuan, Z., Michaelis, E. K., Swerdlow, R. H., Initiative, A. D. N., & Du, H. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02958-0 · Cited by 18
“The etio-pathogenesis of AD is proposed to be a perplexing combination of aging factors, protein aggregates, brain dysmetabolism, and genetic risks [7 – 9].”
BackgroundSelf-citationAssembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping
Ridge, P. G., Wadsworth, M. E., Miller, J. B., Saykin, A. J., Green, R. C., Initiative, T. A. D. N., & Kauwe, J. S. K. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.11.013 · Cited by 17
“In this article, we focus on an important resource for investigating mitochondrial genomic variation and others [25].”
BackgroundGauba, E., Sui, S., Tian, J., Driskill, C. M., Jia, K., Yu, C., Rughwani, T., Wang, Q., Kroener, S., Guo, L., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.018 · Cited by 15
Shahrivar‐Gargari, M., Hamzeh‐Mivehroud, M., Hemmati, S., Mojarrad, J. S., Küçükkılınç, T. T., Ayazgök, B., & Dastmalchi, S. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202000453 · Cited by 15
Faravelli, G., Mondani, V., Mangione, P. P., Raimondi, S., Marchese, L., Lavatelli, F., Stoppini, M., Corazza, A., Canetti, D., Verona, G., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.830006 · Cited by 15
“, 2014) and, impairment in the bio-energetic efficiency (Swerdlow, 2018) are among the most accredited theories.”
BackgroundJu, T., Zhang, Y., Liu, L., Zhao, X., Li, X., Liu, C., Sun, S., & Wu, L. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01419 · Cited by 18
“Therefore, it is evident that the development of neurodegenerative diseases can be influenced by the interplay between chronic inflammation and mitochondrial oxidative stress.”
Inherent potential of mitochondria-targeted interventions for chronic neurodegenerative diseases
Zhou, M., Zheng, M., Liang, S., Li, M., Ma, J., Zhang, S., Song, X., Hu, Y., Lyu, Y., Ou, X., et al. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01507 · Cited by 26
Dar, N. J., Currais, A. J. M., Taguchi, T., Andrews, N., & Maher, P. A. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103692 · Cited by 17
“Despite significant research on mitochondrial dysfunction and its role in cognitive decline, therapeutic interventions remain largely ineffective [4,5].”
Burns, J. M., Morris, J. K., Vidoni, E. D., Wilkins, H., Choi, I., Lee, P., Hunt, S. L., Mahnken, J. D., Brooks, W. M., Lepping, R. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70416 · Cited by 19
Self-citationMitochondrial Dysfunction in Aging: Future Therapies and Precision Medicine Approaches
Jia, L., Wei, Z., Luoqian, J., Wang, X., & Huang, C. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70026 · Cited by 18
Organelle stress in NLRP3 inflammasome: a central mediator of neurodegenerative diseases
Jia, H., Ma, L., Liu, J., Gao, M., Liang, X., Zhang, F., Gao, Y., Liu, M., Jiang, W., Wei, M., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00922-0 · Cited by 20
“Traditionally, mitochondrial impairment is considered an early pathological event that precedes Aβ deposition and tau protein hyperphosphorylation [265].”
The mitochondrial proteomic changes of rat hippocampus induced by 28-day simulated microgravity
Ji, G., Chang, H., Yang, M., Chen, H., Wang, T., Liu, X., Lv, K., Li, Y., Song, B., & Qu, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265108 · Cited by 15
“The mitochondrial dysfunction has also been demonstrated to participate in several diseases such as Alzheimer’s disease [15], cancers [16], cardiovascular diseases [17], Parkinson disease [18], traumatic brain injury and epilepsy [19, 20] etc.”
BackgroundUeno, M., Yoshino, Y., Mori, H., Funahashi, Y., Kumon, H., Ochi, S., Ozaki, T., Tachibana, A., Yoshida, T., Shimizu, H., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215627 · Cited by 17
“41 Currently, extensive research has reported that 42 mitochondrial dysfunction may be associated with 43 various AD pathologies [10].”
BackgroundSabui, A., Biswas, M., Somvanshi, P. R., Kandagiri, P., Gorla, M., Mohammed, F., & Tammineni, P. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.927195 · Cited by 15
“Accumulating evidence suggests that mitochondrial dysfunction is an early event in disease pathogenesis and contributes to synaptic deficits in AD and other neurological disorders (Lin and Beal, 2006; Wang et al., 2014; Swerdlow, 2018).”
BackgroundAmyloid-β Pathology-Specific Cytokine Secretion Suppresses Neuronal Mitochondrial Metabolism
Kuhn, M. K., Fleeman, R. M., Beidler, L. M., Snyder, A. M., Chan, D. C., & Proctor, E. A. (2023) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-023-00782-y · Cited by 14
“Evidence suggests that metabolic dysregulation precedes proteinopathy and participates in the initiation of AD [21, 91].”
BackgroundA case for seeking sex-specific treatments in Alzheimer’s disease
Lynch, M. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1346621 · Cited by 20
Yong, J., & Song, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116688 · Cited by 15
The Role of Non-Coding RNAs in Mitochondrial Dysfunction of Alzheimer’s Disease
Abed, S., Ebrahimi, A., Fattahi, F., Kouchakali, G., Khaniani, M. S., & Derakhshan, S. M. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02262-y · Cited by 17
“Alterations in mtDNA, which encodes 13 essential mitochondrial proteins, can lead to cell death and contribute to various diseases (Swerdlow 2018).”
Role of mitochondrial quality control in neurodegenerative disease progression
Liu, T., Sun, W., Guo, S., Yuan, Z., Zhu, M., Lu, J., Chen, T., Qu, Y., Feng, C., & Yang, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1588645 · Cited by 18
“It has been reported that mitochondria are one of the central players in the pathogenesis of AD and that mitochondrial dysfunction is a driver or predisposing factor in the onset or progression of AD (Sharma C. et al., 2021; Swerdlow, 2018).”
InfluentialVolloch, V., Olsen, B. R., & Rits‐Volloch, S. (2019) · Annals of Integrative Molecular Medicine · doi:10.33597/aimm.01-1005 · Cited by 16
Wang, H., Li, L., Jia, K., Wang, Q., Sui, S., Lin, Y., & He, Y. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001526 · Cited by 14
Jin, X., Long, T., Chen, H., Zeng, Y., Zhang, X., Yan, L. L., & Wu, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710966 · Cited by 14
“Previous literature has indicated that a reduced activity of ADH and ALDH would lead to an excess of acetaldehyde and result in oxidative stress and mitochondrial dysfunctions which have been identified in both familial and sporadic AD (Zhang and Ren, 2011; Chen et al., 2012; Swerdlow, 2018).”
BackgroundTeo, E., Lim, J., Fong, S., Larbi, A., Wright, G. D., Tolwinski, N. S., & Gruber, J. (2019) · Translational Medicine of Aging · doi:10.1016/j.tma.2019.12.002 · Cited by 22
Dominiak, A., Gawinek, E., Banaszek, A. A., & Wilkaniec, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178693 · Cited by 16
“In neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, oxidative damage impairs mitochondrial respiration and leads to the accumulation of dysfunctional mitochondria, often accompanied by increased mtDNA deletions and impaired bioenergetics PD [156–158].”
Mitochondria-Targeted Nanosystems in the Treatment of Central Nervous System Diseases
Zhang, X., Chen, J., Wan, B., Zheng, Y., & Chen, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s562666 · Cited by 17
“14,15 In Parkinson’s disease (PD), abnormal α-synuclein aggregation disrupts mitophagy, leading to accumulated damaged mitochondria in dopaminergic neurons.”
Piccirillo, S., Preziuso, A., Amoroso, S., Serfilippi, T., Miceli, F., Magi, S., & Lariccia, V. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01187-y · Cited by 14
“Several reports have described mitochondrial aberrations in the AD brain [6, 7] and a greater metabolic decline, mainly in regard to the metabolic use of glucose in both the hippocampus and cortex of AD patients in comparison to healthy controls [8].”
BackgroundResultKiss, É., Kins, S., Gorgas, K., Szakács, K. H. V., Kirsch, J., & Kuhse, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084165 · Cited by 18
“…energy and oxygen metabolisms and mitochondrial dysfunction early in AD pathogenesis, before any sign of A β or tau pathology, led to the mitochondrial cascade hypothesis proposing that the aggregations of A β and tau in AD might be a compensatory response to underlying oxidative stress [100].”
BackgroundWang, H., Li, J., Tu, W., Wang, Z., Zhang, Y., Chang, L., Wu, Y., & Zhang, X. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240301 · Cited by 15
“77 Calvo-Rodriguez et al. discovered that NDUFA1 knockdown resulted in higher enzyme activity and ATP levels, to elevated ROS levels.”
Jia, W., Lin, H., Yang, M., Dai, Y.-L., Ding, Y., Xu, W.-S., Wang, S.-N., Cao, Y., Liang, S., Wang, Z., et al. (2024) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2024.08.002 · Cited by 14
Vanacore, R., Eskew, J. D., Sung, L. H., Davis, T., & Smith, A. (2019) · BioMetals · doi:10.1007/s10534-019-00194-4 · Cited by 13
“Furthermore, several of these heme-dependent processes are known to be perturbed in AD (Bai et al. 2013; Nelson and Wang 2010; Onyango et al. 2016; Swerdlow 2018; Volicer et al. 2001;Wang et al. 2008) and clearly are poised to make an impact on APP biology, as does iron and copper and zinc.”
BackgroundCheng, Z.-Y., Hu, Y., Xia, Q.-P., Wang, C., & He, L. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.07.015 · Cited by 13
Fingolimod mitigates synaptic deficits and psychosis‐like behavior in APP/PSEN1 mice
Krivinko, J. M., Erickson, S. L., MacDonald, M. L., Garver, M. E., & Sweet, R. A. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12324 · Cited by 13
The Dual Role of Astrocyte-Derived Exosomes and Their Contents in the Process of Alzheimer’s Disease
Liu, Z., Zhang, H., Liu, S., Hou, Y., & Chi, G. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220698 · Cited by 14
Gao, C., Shang, J., Sun, Z., Xia, M., Gao, D., Sun, R., Li, W., Wang, F., & Zhang, J. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03858-y · Cited by 13
“The amyloid cascade hypothesis does not easily account for various parameters associated with AD [67], while the primary mitochondrial cascade hypothesis assumes mitochondrial pathology hierarchically supersedes Aβ pathology [6].”
BackgroundInfluentialCatalán‐García, M., García‐García, F. J., Moreno, P., Alcarraz‐Vizán, G., Tort‐Merino, A., Milisenda, J. C., Cantó, J., Barcos, T., Cardellach, F., Lladó, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051446 · Cited by 15
“Interestingly, mitochondrial abnormalities, energy failure, respiratory chain impairment, and generation of ROS have also been described in brain aging related to neural loss and synaptic alteration [13].”
BackgroundBusquets, O., Parcerisas, A., Verdaguer, E., Ettcheto, M., Camins, A., Beas‐Zárate, C., Castro-Torres, R. D., & Auladell, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201053 · Cited by 15
“Several additional metabolic alterations have also been identified in AD pathology, including the appearance of oxidative stress [11, 12], dysregulation of autophagic activity [13, 14], and insulin resistance [15–17], among others.”
Clement, A., Madsen, M. J., Kastaniegaard, K., Wiborg, O., Asuni, A. A., & Stensballe, A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220064 · Cited by 13
Guha, S. K., Cheng, A., Carroll, T., King, D. P., Koren, S. A., Swords, S., Nehrke, K. W., & Johnson, G. V. W. (2022) · Genetics · doi:10.1093/genetics/iyac104 · Cited by 11
Xu, X., Wang, H., Bennett, D. A. A., Zhang, Q., Meng, X., & Zhang, H. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.03.002 · Cited by 11
“The deterioration in mitochondrial bio-genesis is either the fundamental incident that triggers A b - or tau-induced neurotoxicity (primary mitochondrial cascade) or a consequence of the amyloid cascade (secondary mitochondrial cascade) that culminates in ADP [9,11,12].”
BackgroundCohen, B. M., & Sonntag, K. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105238 · Cited by 13
Dendrimers—Novel Therapeutic Approaches for Alzheimer’s Disease
Mroziak, M., Kozłowski, G., Kołodziejczyk, W., Pszczołowska, M., Walczak, K., Beszłej, J. A., & Leszek, J. (2024) · Biomedicines · doi:10.3390/biomedicines12081899 · Cited by 12
“As the importance of mitochondrial dysfunction as a part of AD pathogenesis increases, aiming at mitochondrial dysfunction as a therapeutic target seems to be reasonable [76].”
BackgroundMartorana, A., Assogna, M., Lucia, V. D., Motta, C., Bonomi, C. G., Bernocchi, F., Donna, M. G. D., & Koch, G. (2021) · Minerva Medica · doi:10.23736/s0026-4806.21.07448-6 · Cited by 12
Liu, Q., Fu, X., Han, R., Liu, X., Zhao, X., & Wei, J. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1764589 · Cited by 17
“In addition, scholars have found that the mitochondria in Alzheimer’s disease patients and animal models differ from those in individuals not suffering from non-Alzheimer’s disease [38].”
ResultMetodieva, V., Smith, T., & Gunn, F. J. (2022) · eNeuro · doi:10.1523/eneuro.0040-22.2022 · Cited by 16
“In addition, there are multiple mechanisms proposed to drive AD pathology and among the key hallmarks are amyloid pathology (Karran et al., 2011; Hammond et al., 2020), complex brain metabolic dysfunction (Costantini et al., 2008) and mitochondrial aberrations (Swerdlow, 2018).”
BackgroundTian, J., Stucky, C. S., Wang, T., Muma, N. A., Johnson, M. A., & Du, H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230072 · Cited by 14
“Previous studies have consistently found mitochondrial defects in AD brains and animal models of AD-like pathology [36–38].”
Tapella, L., Dematteis, G., Ruffinatti, F. A., Ponzoni, L., Fiordaliso, F., Corbelli, A., Albanese, E., Pistolato, B., Pagano, J., Barberis, E., et al. (2021) · Cell Calcium · doi:10.1016/j.ceca.2021.102480 · Cited by 12
Mosconi, L., Williams, S., Carlton, C., Andy, C., Fauci, F., Zarate, C., Boneu, C., Ajila, T., Nerattini, M., Jett, S., et al. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002512 · Cited by 12
Ultrastructural Evidence of Mitochondrial Dysfunction in Osteomyelitis Patients
Mendelsohn, D. H., Niedermair, T., Walter, N., Alt, V., Rupp, M., & Brochhausen, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065709 · Cited by 11
“Mitochondrial dysfunction is connected to a variety of pathologic conditions including neurodegenerative diseases such as Parkinson’s or Alzheimer’s disease [12,13], as well as diabetes and chronic inflammation [14,15].”
BackgroundTestosterone deficiency worsens mitochondrial dysfunction in APP/PS1 mice
Zhang, T., Chu, Y., Wang, Y., Wang, Y., Wang, J., Ji, X., Zhang, G., Shi, G., Cui, R., & Kang, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1390915 · Cited by 14
“Increasing evidence supports the hypothesis that the mitochondrial dysfunction, as an early event, might trigger amyloid beta (A β ) accumulation and a battery of abnormalities (Swerdlow, 2018), albeit A β may instead incite mitochondrial insult.”
BackgroundXing, Y., Shi, H., Gao, X., Zhu, X., Zhang, D., Fang, L., Wang, J., Liu, C., Wu, D., Wang, X., et al. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c01201 · Cited by 12
Crivelli, S. M., Gaifullina, A., & Chatton, J. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1483708 · Cited by 14
“For details on the mitochondria hypothesis in AD see the review of Swerdlow (2018).”
BackgroundAsokan, K., Sivaraman, S., Nallasamy, K., Jeyavijayan, S., & Paranthaman, S. (2024) · International Journal of Quantum Chemistry · doi:10.1002/qua.70006 · Cited by 12
Ali, I., Adil, M., Imran, M., Qureshi, S. A., Qureshi, S., Hasan, N., & Ahmad, F. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01799-8 · Cited by 13
“Mitochondrial dysfunction also leads to the accumulation of phosphorylated tau (p-tau) and Aβ (β amyloid) peptides in AD [59, 60].”
Panmanee, J., Phanchana, M., Pearngam, P., Petchyam, N., Promthep, K., Wisomka, P., Kutpruek, S., Pannengpetch, S., Prasertporn, T., Mukda, S., et al. (2025) · Cell Biology International · doi:10.1002/cbin.70013 · Cited by 11
“Mitochondrial dysfunction in AD may be related to impaired mitochondrial biogenesis, mitophagy, and changes in mitochondrial dynamics (Swerdlow 2018; Wang et al. 2014).”
Unraveling the mystery of citrate transporters in Alzheimer’s disease: An updated review
Mukherjee, A. G., Mishra, S., Gopalakrishnan, A. V., Kannampuzha, S., Murali, R., Wanjari, U. R., Stany, B. K., Vellingiri, B., Madhyastha, H., Deepankumar, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102726 · Cited by 12
Mitotherapy Restores mitochondrial function and improves cognitive deficits in Alzheimer’s disease
Gupta, T., Rao, A., Devi, V., Kumari, L., Negi, A., Kumar, M., Bharti, R., & Medhi, B. (2025) · Mitochondrion · doi:10.1016/j.mito.2025.102077 · Cited by 11
Pinna, G., & Bortolato, M. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106438 · Cited by 13
Delic, V., Karp, J. H., Klein, J., Stalnaker, K. J., Murray, K. E., Ratliff, W. A., Myers, C. E., Beck, K. D., & Citron, B. A. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22913 · Cited by 11
Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders
Karaki, T., Haniu, H., Matsuda, Y., & Tsukahara, T. (2022) · Biomedicines · doi:10.3390/biomedicines10123126 · Cited by 12
Fighting the Cause of Alzheimer’s and GNE Myopathy
Devi, S., Yadav, R., Chanana, P., & Arya, R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00669 · Cited by 12
“Altered calcium homeostasis affects ATP generation and cause mitochondrial dysfunction (Supnet and Bezprozvanny, 2010; Swerdlow, 2018).”
BackgroundPromising molecular targets for pharmacological therapy of neurodegenerative pathologies
Неганова, М. Е., Aleksandrova, Y. R., Nebogatikov, V. O., Klochkov, S. G., & Ustyugov, A. A. (2020) · Acta Naturae · doi:10.32607/actanaturae.10925 · Cited by 11
The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease
Chen, D., Wigglesworth-Littlewood, S., & Gunn, F. J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00891-4 · Cited by 15
Li, F., Wu, L., Feng, X., Li, Y., & Fan, H. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010070 · Cited by 11
“Mitochondrial dysfunction is a major source of reactive oxygen species (ROS), functioning as both a cause and a consequence of oxidative damage—a hallmark of neurodegeneration [96–98].”
Heat Therapy: Targeting Health, Disease, and Disability
Richey, R. E., Hyldahl, R. D., Kaiser, B. W., Geiger, P. C., Halliwill, J. R., & Minson, C. T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70089 · Cited by 12
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.